WEEKLY WRAP-UP

15TH SEPTEMBER - 18TH SEPTEMBER 2026

PROGRESSIVE®
Your Progress Our Priority...

HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

DOMESTIC:
- Ather Energy on a long growth road, but hurdles remain along the way
- Solar Industries arms ink Rs13,000cr deal to acquire South Africa’s Omnia Holdings
- Samvardhana Motherson commits Rs11,000cr investment in Tamil Nadu
- Vi eyes Rs35,000cr loan to fund next decade's capex
- HFCL’s Board has approved additional investment of ~Rs820cr for expansion of OFC, OF and preform manufacturing capacities
- BHEL Board okays Rs65cr investment in JV NTPC BHEL power projects
- KEC International bags Rs1,303cr orders in India, overseas markets
- Embassy Developments to invest Rs2,000cr in 85-acre Bengaluru project phase 1
- SBI targets Rs2.4lk-cr wealth management market, eyes shareholder value growth
- Dr. Reddy's launches nivolumab biosimilar in India
- Uno Minda to invest Rs1,415cr to boost manufacturing capacity
- Titan SKINN gets in the game for pricier perfumes
- ACME Solar commissions 66.68MW solar capacity and 300MWh BESS capacity in Rajasthan
- Exide India and ExCom, Germany enter into strategic co-operation to strengthen industrial battery business
- Titagarh Rail Systems and BHEL sign contract for long-term maintenance of Vande Bharat sleeper trainsets
- Lemon Tree Hotels expands presence in Punjab
- NBCC India bags multiple orders worth Rs145cr
- Saatvik Green Energy bags order worth Rs1,042cr from SECI
- Tata Hitachi to raise prices from October amid cost pressures
- Infosys expands Indore facility with new software block
- Maharashtra signs Rs27,000cr MoU with Mazagon Dock For 2 million gross tonnage shipbuilding hub
- G R Infraprojects terminates NTPC BESS EPC contracts
- Tata Motors announces price increase for commercial vehicles from October 2026
- HCLTech launches HCLTech Pulse to accelerate AI-led transformation
- Puravankara secures Rs2,600cr redevelopment project in Goregaon West
- Jain Irrigation secures Rs117.96cr empanelment from MSEDCL
- GPT Infra bags order worth Rs484cr from RVNL
- Bharat Forge launches Rs2,000cr QIP at Rs1,851 per share floor price

ECONOMY:
- Food inflation surges to 5.95%, may remain elevated in the short-term
- Bond yields jump on RBI’s OMO announcement, global cues
- October GST Council meet to focus on process reforms: FM

INDUSTRY:
- OMCs head for sharp Q2 rebound as marketing margins recover
- Brent nears USD110 a barrel as West Asia conflict deepens
- India's data center development pipeline through 2030 reaches 3860MW

Please Turn Over

HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

COVERAGE NEWS:

Aurobindo Pharma Ltd: (i) The USFDA inspected Unit-IV, an API manufacturing facility of Apitoria Pharma Private Ltd, a WoS of the company from 07th-11th Sept'26 and concluded with zero observations, (ii) A1 Biochem Labs (India) Pvt. Ltd, a step down subsidiary of the company has subscribed to 10,000 equity shares of USD100 each of A1 Biochem USA Inc. on 11th Sept'26, (iii) The USFDA inspected unit-II, an API manufacturing facility of Apitoria Pharma Pvt. Ltd (WoS) from 07th-15th Sept'26 and the inspection ended with 1 observation.

Gland Pharma Ltd: The Board has approved the acquisition of 100% of equity share capital of Gland Pharma USA Inc., a wholly-owned step-down subsidiary of the company, from Gland Pharma International Pte. Ltd (a wholly-owned subsidiary) for a cost of acquisition of approx. USD501,208. Accordingly, upon completion of the acquisition, Gland US will become a direct wholly-owned subsidiary of the company.

Alembic Pharmaceuticals Ltd: The USFDA has issued an Establishment Inspection Report (EIR) and closed the inspection of the pharmaceuticals' bioequivalence facility of the company in Vadodara, Gujarat.

Alkem Laboratories Ltd: The company has launched NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.

The Week That Went By:

Initially, the Benchmark Index began the truncated week on a strong note but quickly surrendered all its gains. A sharp sell-off across the broader market dragged the Index closer to its key support level of 23,100. However, it gradually recovered during the remainder of the week and eventually settled at 23,346.40, recording a loss of 51.70 points. Sector-wise, Media and FMCG outperformed, while the Defence segment declined sharply by 3.83%. A strong recovery in the Midcap and Smallcap segments helped them outperform the Benchmark Index.

Nifty50=23,346.40 **Sensex30=74,294.96** **Nifty Midcap 100=62,191.25** **Nifty Smallcap100=19,875.70**

HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

NIFTY (WEEKLY)

BANK NIFTY (WEEKLY)

MARKET OUTLOOK

Nifty50 is oscillating within a broad range of 23,100-24,600 and has nearly tested the lower end before bouncing back. We believe the Index will gradually move higher, with immediate resistance at 23,485 and nearby support at 23,250. Similar to Nifty50, **BankNifty** is also fluctuating within a defined range of 55,800-58,000. The immediate resistance and support levels are placed at 56,880 and 55,800, respectively. After successfully retesting its strong support level, the **Capital Market segment** reversed sharply, signalling that bullish momentum remains intact. Within its strong uptrend, the **Defence sector** has formed a bullish Cypher pattern, suggesting that positive momentum is likely to persist. The **FMCG segment** is showing early signs of a trend reversal, supported by a bullish RSI divergence; however, its sustainability remains to be seen. The **Metal sector** continues to form higher tops and higher bottoms and has developed a Doji candlestick pattern near the lower end of its rising channel, indicating the possibility of further upward movement. We remain positive on the **Pharma segment**, which continues to perform in line with our expectations. The **Realty sector** formed a Hammer candlestick pattern after testing strong support and its 50WMA. We will await a confirmatory move before taking any action. Although it is still too early to draw a firm conclusion, **Railway stocks** appear to be nearing the end of their corrective phase, which has lasted more than two years.

HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	(1.31%)
Adani Ports	3.37%
Apollo Hospital	1.23%
Asian Paints	(0.86%)
Axis Bank	0.88%
Bajaj Auto	(2.26%)
Bajaj Finserv	(3.19%)
Bajaj Finance	0.56%
BEL	(2.73%)
Bharti Airtel	3.40%
Cipla	2.09%
Coal India	(3.87%)
Dr. Reddy’s Labs	1.67%
Eicher Motors	(0.19%)
Eternal	1.04%
Grasim	(2.22%)
HCL Tech	3.58%
HDFC Bank	3.21%

HDFC Life	3.95%
Hindalco	0.51%
HUL	0.26%
ICICI Bank	(2.93%)
Indigo	(1.07%)
INFY	1.32%
ITC	0.94%
JioFin	(0.00%)
JSW Steel	0.84%
Kotak Bank	(1.55%)
LT	(1.16%)
M&M	(1.77%)
Maruti	(2.40%)
Max Healthcare	1.12%
Nestle India	(0.79%)
NTPC	(2.92%)
ONGC	0.13%
PowerGrid	0.45%

Reliance	(2.47%)
SBI Life	2.75%
SBIN	0.05%
ShriRam Finance	(1.81%)
Sun Pharma	(0.15%)
Tata Consumer	0.50%
Tata Steel	1.39%
TCS	(4.35%)
Tech Mahindra	(0.25%)
TITAN	(4.21%)
TMPV	0.90%
Trent	0.77%
UltraTech	0.13%
Wipro	(0.34%)

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

SECTORAL GAINER

The **Media segment** advanced 1.08%, outperforming Nifty50. Performance across the segment was mixed, with **Prime Focus (+11.30%)** and **PVR (+7.85%)** emerging as the top performers, while **Sun TV (5.34%)** and **DB Corp (3.15%)** were the major underperformers.

SECTORAL LOSER

The **Defence sector** underperformed, declining 3.83% during the week. Most constituents recorded significant losses, with **Solar Industries (-16.76%)** and **Apollo Micro Systems (-11.98%)** emerging as the biggest underperformers, followed by **Midhani (-6.47%)** and **Data Patterns (-5.98%).** In contrast, **BEML (+5.12%)** and **Aequs (+1.79%)** outperformed. Following the formation of an advanced harmonic pattern, namely a **bullish Cypher,** the sector rebounded strongly, indicating a potential 3–5% upside.

HIGHLIGHTS OF THE WEEK 15 Sept 2026-18 Sept 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai-400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com